{"filings":[{"id":156425,"accession_number":"0001683168-25-002550","cik":1593184,"company_name":"BIOREGENX, INC.","ticker":"BRGX","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioRegenx directors Gary Hennerberg and Gary Kiss resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gary Hennerberg resigned as director effective April 7, 2025.","Gary Kiss resigned as director effective April 4, 2025.","No reason for either resignation was disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7481128.797752809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174866,"accession_number":"0001683168-25-000484","cik":1593184,"company_name":"BIOREGENX, INC.","ticker":"BRGX","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Robert Doran resigns from BioRegenx board effective Jan 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Doran submitted resignation as director on Jan 15, effective Jan 31, 2025.","No reason for departure provided in the filing.","No replacement director was named; board composition will change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7481128.797752809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191822,"accession_number":"0001683168-24-007111","cik":1593184,"company_name":"BIOREGENX, INC.","ticker":"BRGX","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioRegenx appoints Richard Janney to board; forms audit committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Janney appointed to BioRegenx board effective October 7, 2024, until successor elected or removed.","Board formed an audit committee; Janney and existing director Suzanne Bird named as members.","No material plan, contract, or arrangement exists between Janney and BioRegenx; no proposed transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7481128.797752809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191821,"accession_number":"0001683168-24-007019","cik":1593184,"company_name":"BIOREGENX, INC.","ticker":"BRGX","form_type":"8-K/A","filed_at":"2024-10-09T23:59:59+00:00","items":["2.01","3.02","5.01","5.02","5.03","9.01"],"status":"ready","headline":"BioRegenx completes reverse merger; posts $3.6M net loss in 2023 with going concern doubt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger effective March 8, 2024: BioRegenx merged into Findit; registrant renamed BioRegenx, Inc.","Exchanged 851.98M shares and 3,800 Series A preferred for 90% voting control; retired prior preferred and 172.2M common shares.","Audited 2023 results: net loss $3.6M, sales $3.41M, stockholders' deficit $2.07M; auditor flags going concern.","New leadership: William Resides CEO/Interim CFO; new board of 7 directors appointed (8 total including Thomas Powers).","Authorized common increased to 1.5B shares; Series A preferred voting rights corrected to 2,500 votes per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7481128.797752809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208303,"accession_number":"0001683168-24-004996","cik":1593184,"company_name":"BIOREGENX, INC.","ticker":"BRGX","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioRegenx officer and director Sherri Adams resigns effective July 17, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sherri Adams resigned as officer and director effective July 17, 2024, to pursue other business interests.","Departure was not due to any disagreement with the company, its board, or management.","No replacement named; CEO William Resides signed the filing.","Adams' role as officer/director leaves board with at least one vacancy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7481128.797752809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208302,"accession_number":"0001683168-24-004835","cik":1593184,"company_name":"BIOREGENX, INC.","ticker":"BRGX","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Jody M. Walker resigns from BioRegenx board effective July 13, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Walker resigned as director due to retirement, effective July 13, 2024.","Resignation was not due to any disagreement with BioRegenx, its Board or management.","No replacement named; vacancy to be addressed by Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7481128.797752809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225919,"accession_number":"0001683168-24-004095","cik":1593184,"company_name":"BIOREGENX, INC.","ticker":"BRGX","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["4.01","4.02"],"status":"ready","headline":"BioRegenx restates Q1 2024 financials; appoints Weinberg & Co. as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Engaged Weinberg & Company as new independent accountant for fiscal years ended Dec 31, 2023 and 2022, effective June 10, 2024.","Concluded Q1 2024 Form 10-Q and 10-Q/A should no longer be relied upon due to lack of auditor review prior to filing.","Management evaluating restatement impact on financials and internal controls; will file amended 10-Q/A as soon as practical.","No prior consultations with Weinberg on accounting principles or disagreements during past two fiscal years and subsequent interim period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7481128.797752809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225918,"accession_number":"0001683168-24-003582","cik":1593184,"company_name":"BIOREGENX, INC.","ticker":"BRGX","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"BioRegenx dismisses BF Borgers as auditor; BF Borgers barred from SEC practice","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On May 15, 2024, BioRegenx dismissed BF Borgers CPA PC as its independent registered public accounting firm, approved by audit committee.","No disagreements or reportable events occurred during fiscal 2023 or interim period up to dismissal.","BF Borgers is currently not permitted to appear or practice before the SEC, per the filing.","Company did not request BF Borgers to furnish a letter to the SEC regarding the statements made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7481128.797752809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}